This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Willuda, J. Articles by Plückthun, A. Search for Related Content PubMed PubMed Citation Articles by Willuda, J. Articles by Plückthun, A.

High Thermal Stability Is Essential for Tumor Targeting of Antibody Fragments

Engineering of a Humanized Anti-epithelial Glycoprotein-2 (Epithelial Cell Adhesion Molecule) Single-Chain Fv Fragment¹

Department of Biochemistry, University of Zürich, CH-8057 Zürich, Switzerland [J. W., A. H., A. P.]; Division of Oncology, Department of Internal Medicine, University Hospital, CH-8044 Zürich, Switzerland [J. W., R. S., U. Z-W.]; and Center for Radiopharmaceutical Science, Paul Scherrer Institute, CH-5232 Villigen (PSI), Switzerland [R. W., P. A. S.]

The epithelial glycoprotein-2 is abundantly expressed on many solid tumors and is a suitable target for antibody-based therapy. In the present study, an antiepithelial glycoprotein-2 single-chain Fv (scFv) was derived from the hybridoma MOC31 by phage display. Despite its high affinity (K_D = 3.9 x 10^-9 M), however, this antibody fragment failed to significantly enrich at lung tumor xenografts in mice, mostly because of its insufficient thermal stability. To overcome this limitation, the antigen-binding residues of the MOC31 scFv fragment were grafted onto the framework of the highly stable and well-folding anti-c-erbB2 scFv 4D5. Further modification of the resulting 4D5 MOC-A, which was performed by transferring eight additional residues of the heavy chain variable domain core of the parent MOC31 antibody, produced 4D5 MOC-B, resulting in increased serum stability at 37°C and also significantly improved expression behavior while retaining the antigen specificity and affinity of the parent MOC31 scFv. In mice, the scFv 4D5 MOC-B, which was radiolabeled with ^99mtechnetium using a new histidine-tag specific labeling method (Waibel et al., Nature Biotechnol., 17: 897–901, 1999), showed favorable blood clearance and efficient enriches at lung tumor xenografts, with a tumor:blood ratio of 5.25 and a total dose of 1.47% injected dose per gram after 24 h. Biophysical properties such as high thermal stability are thus decisive for whether these molecules are useful in vivo, and our approach may provide a general strategy to solve this problem. This is also the first report of using a humanized anti-EGP-2 scFv in vivo for targeting solid tumors, which is a promising targeting moiety for the diagnostics and therapy of EGP-2-positive tumors in patients.

This article has been cited by other articles:

				E. O. Serebrovskaya, E. F. Edelweiss, O. A. Stremovskiy, K. A. Lukyanov, D. M. Chudakov, and S. M. Deyev Targeting cancer cells by using an antireceptor antibody-photosensitizer fusion protein PNAS, June 9, 2009; 106(23): 9221 - 9225. [Abstract] [Full Text] [PDF]

				J. V. Leyton, T. Olafsen, M. A. Sherman, K. B. Bauer, P. Aghajanian, R. E. Reiter, and A. M. Wu Engineered humanized diabodies for microPET imaging of prostate stem cell antigen-expressing tumors Protein Eng. Des. Sel., March 1, 2009; 22(3): 209 - 216. [Abstract] [Full Text] [PDF]

				A. Honegger, A. D. Malebranche, D. Rothlisberger, and A. Pluckthun The influence of the framework core residues on the biophysical properties of immunoglobulin heavy chain variable domains Protein Eng. Des. Sel., March 1, 2009; 22(3): 121 - 134. [Abstract] [Full Text] [PDF]

				M. Kugler, C. Stein, M. Schwenkert, D. Saul, L. Vockentanz, T. Huber, S. K. Wetzel, O. Scholz, A. Pluckthun, A. Honegger, et al. Stabilization and humanization of a single-chain Fv antibody fragment specific for human lymphocyte antigen CD19 by designed point mutations and CDR-grafting onto a human framework Protein Eng. Des. Sel., March 1, 2009; 22(3): 135 - 147. [Abstract] [Full Text] [PDF]

				S. Hussain, A. Pluckthun, T. M. Allen, and U. Zangemeister-Wittke Antitumor activity of an epithelial cell adhesion molecule targeted nanovesicular drug delivery system Mol. Cancer Ther., November 1, 2007; 6(11): 3019 - 3027. [Abstract] [Full Text] [PDF]

				B. J. Stish, H. Chen, Y. Shu, A. Panoskaltsis-Mortari, and D. A. Vallera Increasing Anticarcinoma Activity of an Anti-erbB2 Recombinant Immunotoxin by the Addition of an Anti-EpCAM sFv Clin. Cancer Res., May 15, 2007; 13(10): 3058 - 3067. [Abstract] [Full Text] [PDF]

				S. Hussain, A. Pluckthun, T. M. Allen, and U. Zangemeister-Wittke Chemosensitization of carcinoma cells using epithelial cell adhesion molecule-targeted liposomal antisense against bcl-2/bcl-xL Mol. Cancer Ther., December 1, 2006; 5(12): 3170 - 3180. [Abstract] [Full Text] [PDF]

				S. Kubetzko, E. Balic, R. Waibel, U. Zangemeister-Wittke, and A. Pluckthun PEGylation and Multimerization of the Anti-p185HER-2 Single Chain Fv Fragment 4D5: EFFECTS ON TUMOR TARGETING J. Biol. Chem., November 17, 2006; 281(46): 35186 - 35201. [Abstract] [Full Text] [PDF]

				C.-Y. Xiong, A. Natarajan, X.-B. Shi, G. L. Denardo, and S. J. Denardo Development of tumor targeting anti-MUC-1 multimer: effects of di-scFv unpaired cysteine location on PEGylation and tumor binding Protein Eng. Des. Sel., August 1, 2006; 19(8): 359 - 367. [Abstract] [Full Text] [PDF]

				S. J. Demarest, G. Chen, B. E. Kimmel, D. Gustafson, J. Wu, J. Salbato, J. Poland, M. Elia, X. Tan, K. Wong, et al. Engineering stability into Escherichia coli secreted Fabs leads to increased functional expression Protein Eng. Des. Sel., July 1, 2006; 19(7): 325 - 336. [Abstract] [Full Text] [PDF]

				M.H. Parker, Y. Chen, F. Danehy, K. Dufu, J. Ekstrom, E. Getmanova, J. Gokemeijer, L. Xu, and D. Lipovsek Antibody mimics based on human fibronectin type three domain engineered for thermostability and high-affinity binding to vascular endothelial growth factor receptor two Protein Eng. Des. Sel., September 1, 2005; 18(9): 435 - 444. [Abstract] [Full Text] [PDF]

				V. Cortez-Retamozo, N. Backmann, P. D. Senter, U. Wernery, P. De Baetselier, S. Muyldermans, and H. Revets Efficient Cancer Therapy with a Nanobody-Based Conjugate Cancer Res., April 15, 2004; 64(8): 2853 - 2857. [Abstract] [Full Text] [PDF]

				C. P. Graff, K. Chester, R. Begent, and K.D. Wittrup Directed evolution of an anti-carcinoembryonic antigen scFv with a 4-day monovalent dissociation half-time at 37{degrees}C Protein Eng. Des. Sel., April 1, 2004; 17(4): 293 - 304. [Abstract] [Full Text] [PDF]

				F. Le Gall, U. Reusch, M. Little, and S. M. Kipriyanov Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody Protein Eng. Des. Sel., April 1, 2004; 17(4): 357 - 366. [Abstract] [Full Text] [PDF]

				J. Krauss, M. A.E. Arndt, A. C.R. Martin, H. Liu, and S. M. Rybak Specificity grafting of human antibody frameworks selected from a phage display library: generation of a highly stable humanized anti-CD22 single-chain Fv fragment Protein Eng. Des. Sel., October 1, 2003; 16(10): 753 - 759. [Abstract] [Full Text] [PDF]

				C. Di Paolo, J. Willuda, S. Kubetzko, I. Lauffer, D. Tschudi, R. Waibel, A. Pluckthun, R. A. Stahel, and U. Zangemeister-Wittke A Recombinant Immunotoxin Derived from a Humanized Epithelial Cell Adhesion Molecule-specific Single-Chain Antibody Fragment Has Potent and Selective Antitumor Activity Clin. Cancer Res., July 1, 2003; 9(7): 2837 - 2848. [Abstract] [Full Text] [PDF]

				J. Willuda, S. Kubetzko, R. Waibel, P. A. Schubiger, U. Zangemeister-Wittke, and A. Pluckthun Tumor Targeting of Mono-, Di-, and Tetravalent Anti-p185HER-2 Miniantibodies Multimerized by Self-associating Peptides J. Biol. Chem., April 20, 2001; 276(17): 14385 - 14392. [Abstract] [Full Text] [PDF]